ADVFN US – Market Content Editor
-
Eli Lilly shares gain after Novo Nordisk obesity drug falls short in trial
Shares of Eli Lilly (NYSE:LLY) rose 2.8% to $1,037 in premarket trading Monday after rival Novo Nordisk (CSE:NOVOb) reported that its experimental obesity treatment CagriSema failed to meet a key clinical trial objective. Novo Nordisk said the study did not demonstrate that CagriSema was non-inferior to Eli Lilly’s Tirzepatide in reducing body weight. Trial data…
-
Allurion shares soar after FDA clears Smart Capsule weight-loss device
Allurion Technologies (NYSE:ALUR) shares jumped about 40% after the company announced it had received U.S. Food and Drug Administration approval for its Allurion Gastric Balloon System, which includes the Allurion Smart Capsule. The FDA granted premarket approval for the weight-loss treatment, opening access to an estimated 80 million Americans with obesity who fall within the…
-
FTC Solar Stock Gains After Signing Three-Year Supply Agreement in South Africa
FTC Solar Inc. (NASDAQ:FTCI) shares rose 4.9% to $8.59 in premarket trading Monday after the company revealed a new three-year supply partnership with South African solar procurement firm Lubanzi Inala. Under the deal, FTC Solar will provide roughly 840 megawatts of solar tracking systems to Lubanzi over the duration of the agreement, with the first…
-
Enhabit Shares Surge After Kinderhook Agrees $1.1 Billion Takeover
Enhabit Inc. (NYSE:EHAB) shares surged more than 22% in premarket trading Monday after the home health and hospice provider announced a definitive agreement to be acquired by private equity firm Kinderhook Industries in an all-cash deal valued at roughly $1.1 billion. Under the terms of the agreement, Enhabit shareholders will receive $13.80 per share in…
-
Psyence Biomedical Shares Rise Following Equity Investment Agreement
Psyence Biomedical Ltd. (NASDAQ:PBM) shares climbed 4.4% in premarket trading Monday after the company announced plans to acquire an equity stake in Psyence Labs Ltd. through a share-for-share transaction. The deal comes after Psyence Labs exercised a previously disclosed put option. Under the agreement, Psyence Biomedical will acquire 2,900 Psyence Labs shares, representing a total…
-
MoonLake Shares Climb on Encouraging axSpA Trial Results
MoonLake Immunotherapeutics (NASDAQ:MLTX) shares advanced 6.6% in premarket trading Monday after the company reported positive topline findings from its Phase 2 S-OLARIS study evaluating sonelokimab for axial spondyloarthritis (axSpA). According to the company, 81% of patients receiving sonelokimab achieved an ASAS40 response at Week 12, indicating at least a 40% improvement across key disease measures.…
-
Vertical Aerospace Shares Dip Following Raymond James Downgrade
Vertical Aerospace Ltd. (NYSE:EVTL) shares declined 2.7% in premarket trading Monday after Raymond James lowered its rating on the stock from Market Perform to Underperform, citing financial and competitive concerns. Raymond James analyst Savanthi Syth pointed to uncertainty surrounding the company’s funding runway and increasing competition within the electric aviation sector. The analyst estimates Vertical…
-
Axsome Shares Slip Despite Fourth-Quarter Earnings Beat and Strong Revenue Growth
Axsome Therapeutics Inc. (NASDAQ:AXSM) reported fourth-quarter results that topped analyst forecasts, although the company’s shares fell 2.03% in premarket trading following the announcement. The biopharmaceutical company posted a quarterly loss of $0.56 per share, outperforming the consensus expectation for a loss of $0.73 per share. Revenue for the quarter came in at $196.0 million, exceeding…
-
ImmunityBio Reports Strong 2025 Revenue Growth Alongside Global Expansion and Regulatory Progress
ImmunityBio, Inc. (NASDAQ:IBRX), a commercial-stage immunotherapy company, disclosed significant financial and operational progress for 2025 in a newly filed SEC Form 8-K, highlighting sharp revenue growth, expanding product approvals and advancing international partnerships. Financial Performance The company reported full-year net product revenue of $113 million for 2025, representing an approximately 700% increase compared with the…
-
Tian Ruixiang in Advanced Talks on Asia-Pacific InsurTech Combination While Pursuing Bitcoin Acquisition Strategy
Tian Ruixiang Holdings Ltd (NASDAQ:TIRX) said it is in advanced, final-stage discussions regarding a potential strategic business combination with a leading insurance technology company operating across the Asia-Pacific region. The company also confirmed it continues to advance its previously announced strategy to acquire Bitcoin (BTC), part of a broader effort aimed at strengthening long-term shareholder…